Artivion, Inc. (AORT) Stock Analysis
Range Bound setup
Healthcare · Medical Devices
Sell if holding. Momentum 1.6/10 is below the 5.0 floor at $35.45 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: BioGlue; Concentration risk — Product: aortic stent grafts.
Artivion manufactures, processes, and distributes medical devices and implantable human tissues for cardiac and vascular surgery in two segments: Medical Devices (aortic stent grafts, On-X mechanical heart valves, BioGlue surgical adhesive) and Preservation Services (implantable... Read more
Sell if holding. Momentum 1.6/10 is below the 5.0 floor at $35.45 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: BioGlue; Concentration risk — Product: aortic stent grafts. Chart setup: RSI 41 mid-range, Bollinger mid-band. Score 5.1/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductBioGlue10-K Item 1A: 'BioGlue is a significant source of our revenues, and as such, any risk adversely affecting our BioGlue products or business would likely be material to our financial results'
- HIGHProductaortic stent grafts10-K Item 1A: 'Aortic stent grafts are a significant source of our revenues, and as such, any risk adversely affecting aortic stent grafts would likely be material to our financial results'
- HIGHProductOn-X products10-K Item 1A: 'On-X products are a significant source of our revenues, and as such, any risk adversely affecting our On-X products or business would likely be material to our financial results'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 1.6/10 is below the 5.0 floor at $35.45 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: BioGlue; Concentration risk — Product: aortic stent grafts. Chart setup: RSI 41 mid-range, Bollinger mid-band. Prior stop was $33.05. Score 5.1/10, moderate confidence.
Take-profit target: $44.87 (+26.3% upside). Prior stop was $33.05. Stop-loss: $33.05.
Concentration risk — Product: BioGlue; Concentration risk — Product: aortic stent grafts; Earnings in 7 days (event risk).
Artivion, Inc. trades at a P/E of 165.0 (forward 30.0). TrendMatrix value score: 5.6/10. Verdict: Sell.
13 analysts cover AORT with a consensus score of 4.2/5. Average price target: $52.
What does Artivion, Inc. do?Artivion manufactures, processes, and distributes medical devices and implantable human tissues for cardiac and...
Artivion manufactures, processes, and distributes medical devices and implantable human tissues for cardiac and vascular surgery in two segments: Medical Devices (aortic stent grafts, On-X mechanical heart valves, BioGlue surgical adhesive) and Preservation Services (implantable cardiac and vascular tissues). Revenue comes from hospitals and cardiac/vascular surgeons globally, primarily through direct sales and distributor relationships. The company is dependent on single-source suppliers for key product components including BioGlue delivery devices and the NEXUS product line made solely by En